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Drugs for Neglected Diseases initiative is a not for profit organisation founded in 2003 by 
research institutions from endemic countries affected by neglected diseases and Doctors 
without Borders  with the objective of developing 11 to 13 treatments by 2018. The 
diseases that were selected are Human African Trypanosomiasis, Chagas Disease, 
Visceral and Cutaneous Leishmaniasis, Malaria, later onchocerciasis, lymphatic 
Filariasis and pediatric HIV were included. 
 
Soon after its creation, the Lelishmaniasis East African Platform (LEAP) was set-up, 
bringing clinical experts, academic institutions, Ministries of Health representatives, 
NGOs, from Ethiopia, Kenya, Uganda and Sudan with the objective of promoting and 
conducting clinical trials for the development of new treatment options for patients 
suffereing from leishmaniasis.  Since then DNDi has conducted several important 
studies in the Gedaref State together with the University of Khartoum, the Federal 
Ministry of Health as well as MSF. 
 
In 2010, based on the results of the first landmark trial, the combination of SSG and 
Paromomycin was adopted by the WHO experts as 1st line treatment for East Africa and 
also added to the treatment guidelines in Sudan.  Following this, the Ministry of Health in 
Sudan, MSF and DNDi engaged into a large pharmacovigilance study assessing the 
SSG-PM combination’s effectiveness in field conditions. The results of this large study 
were presented in Bahir Dar in October 2014, confirming the good results of this 
treatment.  
 
In total, in Sudan, over 2000 patients were randomized into clinical trials whilst another 
2000 directly received treatment and not included in the trials.  
The development of Professor El Hassan Centre for Tropical Medicine in Dooka was 
supported. 
 
Since 2012, DNDi engaged into advocacy supporting activities to bring more attention to 
mycetoma as a public health issue, together with the Mycetoma Research Centre in 
Khartoum. 
 
Sudan is highly affected by kala-azar as well as other neglected diseases. DNDi will 
continue to get more involved with Sudan research experts, in Leishmania as well as in 
other prevalent disease as part of our research program portfolio.  
 
